Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers from NDORMS, the Department of Oncology and Wellcome Centre for Human Genetics attend the Big Bang Fair 2018 to inspire the next generation of scientists.

Last week three departments and units across the Medical Sciences Division - NDORMS, the Department of Oncology, and the Wellcome Centre for Human Genetics - attended the Big Bang Science Fairthe largest celebration of science, technology, engineering and maths (STEM) for young people in the UK. With an audience aged mainly 7-19, the event was a fantastic opportunity to educate and inspire the next generation of scientists. 

A variety of activities were used to engage visitors with the fantastic world of medical science. Researchers from the Kennedy Institute of Rheumatology (NDORMS) used a giant model of a gut wall, complete with magnetic plush bacteria and viruses, to talk about the microbes in our digestive tract and how important they are to our health, while children were also offered the chance to try keyhole surgery on a model knee. 

DNA Damage 2.jpg

'DNA Damage Wool Bags' from the Wellcome Centre for Human Genetics offered an insight into the size and complexity of our DNA; visitors had 30 seconds to rummage through miles of DNA wool to find the different kinds of damage DNA undergoes. A researcher from the Oxford Vaccine Group (Department of Paediatrics) also helped children to understand the complexity of DNA by showing them how to decode strings of DNA sequences to uncover the hidden messages. 

Finally, Oncology researchers were on hand with chocolate CT scans to teach visitors about the part X-rays and CT scans can play in diagnosing cancer. 

Oncology.jpg

Congratulations to all researchers who took part! 

See some highlights from the Big Bang Fair

Find out more about Public Engagement with Research across the Medical Sciences Division

Similar stories

New form of gift wrap drives male reproductive success

General Research

A study from the Department of Physiology, Anatomy and Genetics (DPAG) has identified a new communication mechanism that ensures the transfer of a complex mix of signals and nutrients required for successful reproduction between males and females.

PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19

Coronavirus COVID-19 General Research

In March 2020, the UK-wide Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE) trial was established as a flexible, platform randomised clinical trial to test a range of potential treatments for COVID-19 that might be suitable for use in the community to help people recover more quickly and prevent the need for hospital admission. The trial is one of three national platform trials for COVID-19 treatments, and complements the RECOVERY and REMAP-CAP trials that focus on hospitalised patients.

Early animal studies yield promising results for new potential COVID-19 vaccine

Coronavirus COVID-19 General Research

Studies carried out in the MRC Human Immunology Unit (MRC HIU) in collaboration with the Pirbright Institute have shown that a new potential vaccine against COVID-19, named RBD-SpyVLP, produces a strong antibody response in mice and pigs, providing vital information for the further development of the vaccine. Although this type of vaccine is not a competitor for the first wave of vaccines, it is hoped that it will be useful as a standalone vaccine or as a booster for individuals primed with a different COVID-19 vaccine.

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.